Kornimate/medical-research-clean huggingface dataset:
defining the extent and grade of prostate cancer using dynamic contrast enhanced diffusion weighted and bold mri

Conditions: Prostate Cancer

Summary: the purpose of this study is to determine the ability of functional mri techniques to detect, measure and locate intra-prostatic cancer.

the purpose of this study is to determine the ability of functional mri techniques \[high resolution dynamic contrast enhanced mri (hr-dce-mri), diffusion weighted mri (dwi) and bold mri\] to detect, measure and locate intra-prostatic cancer. 70 patients undergoing mri for staging of prostate cancer prior to radical prostatectomy will be studied. results of mri obtained prior to surgery will be correlated with pathologic specimens to determine mri accuracy.

Eligibility criteria:
patients will be recruited from the university health network (uhn). eligible patients will be undergoing radical prostatectomy for prostate cancer at uhn. patients with a contraindication to mri or mri contrast agents, claustrophobia, renal failure, allergy to mri contrast agents, or prior hormonal therapy or radiation therapy for prostate cancer, a biopsy within 3 weeks of the surgical date or active prostatitis will be excluded.
clinical evaluation of two silicone hydrogel contact lenses

Conditions: Myopia

Summary: this study is to compare the short-term clinical performance and subjective acceptance of two silicone hydrogel soft contact lenses.

this is a double-masked, randomized, bilateral crossover study to compare the short-term clinical performance of two silicone hydrogel soft contact lenses. each lens type is worn for approximately six hours on separate study days, in random sequence.

Eligibility criteria:
inclusion criteria: 1. they are aged between 18 and 40 years. 2. they understand their rights as a research subject and are willing and able to sign a statement of informed consent. 3. they are willing and able to follow the protocol. 4. they have successfully worn contact lenses within six months of starting the study. 5. they can be satisfactorily fitted with the study contact lenses. 6. they have a contact lens spherical prescription between -0.25 to - 6.00d (inclusive) based on the ocular refraction. 7. they have a spectacle cylindrical correction of -0.75d or less in each eye based on the ocular refraction. 8. they own and habitually wear single vision spectacles. 9. they can attain at least 0.20 logmar distance high contrast visual acuity in each eye, with the study lenses. 10. they agree not to participate in other clinical research while enrolled on this study. exclusion criteria: 1. they have an ocular disorder which would normally contraindicate contact lens wear. 2. they have a systemic disorder which would normally contraindicate contact lens wear. 3. they are using any topical medication such as eye drops or ointment. 4. they are aphakic. 5. they have had corneal refractive surgery. 6. they have any corneal distortion resulting from previous hard or rigid lens wear or have keratoconus. 7. they are pregnant or breastfeeding. 8. they have any ocular abnormality which would, in the opinion of the investigator, normally contraindicate contact lens wear or pose a risk to study personnel; or they have any immunosuppressive disease (eg hiv) or a history of anaphylaxis or severe allergic reaction. 9. they have grade 3 or greater of any of the following ocular surface signs: corneal oedema, corneal vascularisation, corneal staining, tarsal conjunctival changes or any other abnormality, which would normally contraindicate contact lens wear. 10. they have taken part in any other clinical trial or research, within two weeks prior to starting this study, which may impact on this particular work.
retroclavicular block in vascular surgey

Conditions: Pain Management

Summary: the retroclavicular (coracoid) approach for brachial plexus anesthesia is recognized for its facility and simplicity to perform . the block has been well described in the anesthesia community since it was first introduced by hebbard and royse in 2007 . in 2017, luftig . first described the block's use in the ed setting for a variety of indications . because of its different needle entry point, the retro clavicular (rcb) approach offers an almost perpendicular needle-ultrasound (us) beam angle.

regional anesthesia (ra) offers several advantages over general anesthesia (ga) for upper limb orthopedic surgery. one of the advantages is the improvement in postoperative pain, which leads to decreased use of postoperative opioids needs and reduces the recovery time for patients . a variety of approaches for regional blockade for upper extremity surgery have been described. dexamethasone is a corticosteroid drug that has been used as an adjuvant to reduce postoperative pain. the use of peri neural dexamethasone (i.e. dexamethasone added to the local anesthesia solution) as an adjuvant to peripheral nerve block to improve analgesia provided by local anesthetic alone . peri neural dexamethasone, as an adjuvant to peripheral nerve block, has been associated with faster onset of anesthesia , longer duration of anesthesia/analgesia decreased postoperative pain intensity and decreased postoperative analgesia requirements compared with local anaesthetic alone . the exact mechanism by which dexamethasone reduces pain is not known. the decrease in pain intensity and the prolonged analgesia attained with the use of perineural dexamethasone may be the result of a local, or systemic action, or both . dexamethasone may act locally on glucocorticosteroid receptors to induce vasoconstriction, thereby decreasing systemic absorption of local anaesthetics . other potential mechanisms of action include suppression of c-fibre transmission of pain signals and direct action on the nerve cell to reduce neural discharge . dexamethasone may act systemically by reducing the inflammatory response caused by surgical tissue injury .

Eligibility criteria:
inclusion criteria: * patients undergoing upper limb vascular surgey . exclusion criteria: * - contraindications to regional block (coagulopathy, infection at the needle insertion site, or diaphragmatic paralysis). * altered conscious level. * pregnancy. * body mass index (bmi \> 35). * patients who have difficulty understanding the study protocol. * patients who have any known contraindication to study medications. * patient refusal.
the development of the simulation curriculum and ai-incorporated assessment tool for transesophageal echocardiography

Conditions: Out-Of-Hospital Cardiac Arrest

Summary: this study aims to establish a novel transesophageal echocardiography (tee) simulation curriculum based on previous research results and suggestions from the american college of emergency physicians. to better evaluate the efficacy of the curriculum, an evaluation model utilizing artificial intelligence (ai) would be introduced. the study population is at least 60 junior physicians in the emergency department or other departments interested in tee. after the curriculum, junior physicians could utilize tee on cardiac arrest patients and improve diagnostic accuracy and patient outcomes.

this study aims to establish a novel tee simulation curriculum based on previous research results and suggestions from the american college of emergency physicians. to better evaluate the efficacy of the curriculum, an evaluation model utilizing artificial intelligence (ai) would be introduced. the study population is at least 60 junior physicians in the emergency department or other departments interested in tee. after the curriculum, junior physicians could utilize tee on cardiac arrest patients and improve diagnostic accuracy and patient outcomes.

Eligibility criteria:
inclusion criteria: emergency physicians interested in tee learning. exclusion criteria: emergency physicians are not interested in tee learning.
ureteral stent study

Conditions: Urolithiasis

Summary: the purpose of this study is to evaluate the feasibility of the cook ureteral stent to reduce post-stent placement pain and urinary symptoms in patients following ureteroscopy for urolithiasis.


Eligibility criteria:
inclusion criteria: * patient is undergoing ureteroscopy for urolithiasis in which temporary ureteral stenting is indicated exclusion criteria: * patient is unwilling or unable to sign and date the informed consent * patient is unwilling to comply with the follow-up study schedule * patient is pregnant, breast-feeding, or planning to become pregnant during the course of the study * patient is currently taking anti-cholinergic or other anti-spasm medications * patient is currently taking sildenafil, tadalafil, or vardenafil * patient has a known sensitivity to alpha-blocker medications * patient is currently undergoing chemotherapy or radiation therapy * patient has an active urinary tract infection * patient is in chronic renal failure, on hemodialysis, or on chronic peritoneal dialysis * patient requires bilateral shock wave lithotripsy, bilateral stents, or has bilateral symptomatic kidney stones * patient has had a ureteral stent within the past three months in either ureter * patient is unable to accurately detect or report bladder function or pain * patient has chronic pain

Keywords: ureteroscopy for urolithiasis
68ga-bnu-psma pet/ct in patients with various types of cancer

Conditions: Tumor; Positron-Emission Tomography; Metastasis

Summary: to evaluate the potential usefulness of 68ga-bnu-psma positron emission tomography/computed tomography (pet/ct) for the diagnosis of primary and metastatic lesions in various types of cancer.

subjects with various types of cancer underwent 68ga-bnu-psma pet/ct either for an initial assessment or for recurrence detection. tumor uptake was quantified by the maximum standard uptake value (suvmax). the sensitivity, specificity, positive predictive value (ppv), negative predictive value (npv) and accuracy of 68ga-bnu-psma pet/ct were calculated.

Eligibility criteria:
inclusion criteria: * (i) adult population (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include mri, ct, tumor markers and pathology report); (iii) patients who had scheduled 68ga-bnu-psma pet/ct scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the clinical research ethics committee; (v) healthy volunteers(aged 18 years or order). exclusion criteria: * (i) patients with pregnancy; (ii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
avoidance-driven decision making and learning in anorexia nervosa and bulimia nervosa

Conditions: Bulimia Nervosa; Anorexia Nervosa

Summary: the purpose of this study is to investigate areas of the brain responsible for avoidance learning in adults with eating disorders using brain imaging techniques, computer tasks, and self-report questionnaires and interviews. the investigators will study changes in brain activity using a procedure called functional magnetic resonance imaging (fmri). this study will include 78 women with an eating disorder (26 with anorexia nervosa \[an\], 26 with bulimia nervosa \[bn\]) and 26 healthy controls (hc) aged 18-39. aim 1: evaluate behavioral differences in active and passive avoidance learning in eating disorders and associations with symptoms. aim 2: evaluate whether corticostriatal and limbic-prefrontal fmri bold response associated with avoidance learning differs in eating disorders relative to healthy controls and relates to symptoms. aim 3: evaluate whether functional connectivity of avoidance learning neural circuity differs in eating disorders relative to healthy controls.


Eligibility criteria:
inclusion criteria: eating disorder group: * between the ages of 18 and 39 years old * meet dsm-v criteria for anorexia nervosa or bulimia nervosa healthy controls: * between the ages of 18 and 39 years old * have maintained 85% to 120% ideal body weight since menarche exclusion criteria: * psychotic illness/other mental illness requiring hospitalization * current dependence on drugs or alcohol defined by dsm iv criteria. additionally, positive test results for drug use on the day of the scan, apart of marijuana, will result in cancelling or rescheduling the scan because acute use will impact mri measures. * physical conditions (e.g. diabetes mellitus, pregnancy) known to influence eating or weight * neurological disorder, neurodevelopmental disorder, or history of head injury with \>30 min loss of consciousness * any contraindication to undergoing an mri * primary obsessive compulsive disorder or primary major depressive disorder additional exclusion criteria for ed group: * if taking other psychotropic medication, any change in dosage in the 2 weeks before scanning additional exclusion criteria for healthy control group: * meet criteria for the diagnosis of any psychiatric disorder currently * any history of binge eating or purging behaviors, including self-induced vomiting, laxative or diuretic misuse * use of any psychoactive or other medication known to affect mood or concentration in the last 3 months
longitudinal coverage with evidence development study on micra leadless pacemakers

Conditions: Bradycardia

Summary: the primary purpose of the study is to meet the cms mandated coverage with evidence development requirement in the national coverage determination for leadless pacemakers as they apply to medtronic micra devices. the study uses administrative claims data of the medicare population implanted with single-chamber ventricular pacemakers. patients are enrolled through submission of claims or encounter data to cms.

micra ced study is a study of the medicare beneficiary population implanted with single-chamber ventricular pacemakers, and will be executed by analyzing administrative claims data. the study consists of two primary objectives: estimate the: (1) acute overall complication rate and (2) the 2-year survival rate of patients implanted with a micra leadless pacemaker. as part of the secondary objectives of the study, a comparative analysis of micra leadless pacemakers to single-chamber ventricular transvenous pacemakers will be conducted. the analysis will be in cms claims data and is subject to a central irb. however, individual hospitals are not engaged in research and local irb oversight is not necessary.

Eligibility criteria:
inclusion criteria: • medicare beneficiaries implanted with a leadless pacemaker (cpt 0387t or 33274 or icd-10 pcs 02hk3nz) on or after the study start date will be included in the study. or • medicare beneficiaries with implanted with a full system single-chamber ventricular transvenous pacemaker (cpt 33207 or icd-10 pcs 0jh605z or 0jh604z and 02hk3jz) on or after the study start date. exclusion criteria: • none
characteristics and treatment patterns of patients with sickle cell disease in globin research network for data and discovery registry

Conditions: Sickle Cell Disease

Summary: this was a retrospective observational cohort study. this study was a secondary analysis of individuals with sickle cell disease (scd) enrolled in the grndad registry.


Eligibility criteria:
inclusion criteria: * diagnosis of scd. * signed consent to participate in grndad registry. exclusion criteria: • none identified at this time.
effect of hericium erinaceus on clinical patients with hearing impairment

Conditions: Tinnitus

Summary: this study aims to investigate the effect of hericium erinaceus on clinical patients with hearing impairment and possible mechanisms. subjects with hearing impairment will be enrolled and randomly divided into experimental or control group supplemented with hericium erinaceus (430 mg/kg/day) or placebo, respectively for eight months. basic characteristics will be evaluated at baseline by questionnaire. the hearing, liver and kidney functions, and neurotrophic factors will be examined at baseline, 4th month and 8th month.

this study aims to investigate the effect of hericium erinaceus on clinical patients with hearing impairment and possible mechanisms. subjects with hearing impairment will be enrolled. inclusion criteria were 50 to 79 years old with symmetric sensorineural hearing loss, subjective sensorineural tinnitus, and all frequencies differed of ears less than 15 db. exclusion conditions were patients with abnormal liver and kidney function, normal hearing, severe and very severe hearing loss, no tinnitus or non-subjective sensorineural tinnitus, moderate or more cognitive impairment, patients unable to understand the details of this study or patients unable to co-examine, history of alcohol or drug abuse, history of high ambient noise exposure, bone tone air gap of pure tone hearing threshold greater than 10 db, and audiogram 4 khz air conduction threshold greater than 8 khz, 20 db airway threshold, hearing impairment before age 30, and inability to understand the details of this study. participants will randomly divide into experimental or control group supplemented with hericium erinaceus (430 mg/kg/day) or placebo, respectively for eight months by a prospective, randomized, double-blind approach. basic characteristics will be evaluated at baseline by questionnaire. the status of hearing, and cbc, got, gpt, bun, creatinine, ngf and bdnf expressions in blood will be examined at baseline, 4th month and 8th month.

Eligibility criteria:
inclusion criteria: * patients aged 50 to 79 years old with symmetric sensorineural hearing loss, subjective sensorineural tinnitus, and all frequencies differed of ears less than 15 db. exclusion criteria: * patients with abnormal liver and kidney function, normal hearing, severe and very severe hearing loss, no tinnitus or non-subjective sensorineural tinnitus, moderate or more cognitive impairment , patients unable to understand the details of this study or patients unable to co-examine, history of alcohol or drug abuse, history of high ambient noise exposure, bone tone air gap of pure tone hearing threshold greater than 10 db, and audiogram 4 khz air conduction threshold greater than 8 khz, 20 db airway threshold, hearing impairment before age 30, and inability to understand the details of this study.

Keywords: hericium erinaceus hearing
the effect of health education and yoga on menopause symptoms and quality of life according to pender's model

Conditions: Quality of Life; Health Education; Yoga; Menopause Symptoms

Summary: the aim of the study is to examine the effect of health education and yoga intervention prepared according to pender's health promotion model on menopausal women's "menopause-specific quality of life" compared to routine care. health education and yoga will be conducted by a certified and responsible investigator. after obtaining informed consent from the participants, the scales will be applied before and after health education and yoga practice.

it is known that the symptoms experienced by women during menopause affect the woman's quality of life. many methods have been used in the literature to manage menopause symptoms. however, this study is important to present health education prepared according to pender's health development model, which will enable women to develop health responsibility awareness, and to manage and alleviate menopausal symptoms of yoga practice planned in this context, to determine its effect on quality of life and to provide a source for literature. research hypotheses: h0= there is no difference between menopause-specific quality of life score averages. h1= there is a difference between menopause-specific quality of life score averages. research question: 1.what are the yoga transformation effect scale scores of the participants in the experimental group after the yoga intervention? data collection tools three data collection forms will be used in the research. there is an introductory information form, "menopause-specific quality of life scale", and "yoga transformation scale".

Eligibility criteria:
inclusion criteria: * been in menopause for at least 1 year and at most 5 years * experiencing menopausal symptoms at least 3 to 4 times a week in the last 3 months * those who have no physical disability to practice yoga * able to speak and understand turkish exclusion criteria: * those who receive hormone replacement therapy * those who have undergone surgical menopause * having done yoga before

Keywords: menopause symptoms health education yoga quality of life
evaluate the safety and efficacy of car-t cells in the treatment of r/r neuromyelitis optica

Conditions: Neuromyelitis Optica

Summary: this is a single-arm, open-label, single-center, phase i study. the primary objective is to evaluate the safety of cd19 car-t therapy for patients with relapsed or refractory neuromyelitis optica, and to evaluate the pharmacokinetics of cd19 car-t in patients.


Eligibility criteria:
inclusion criteria: * 1. age 18-60 and gender unlimited; * 2. nmosd diagnosed based on the 2015 nmosd international consensus diagnostic criteria; * 3. diagnostic criteria for aqp4-igg positive nmosd diagnostic criteria for aqp4-igg positive nmosd 1. at least 1 core clinical feature 2. using reliable methods to detect positive aqp4-igg (cba method) 3. exclude other diagnoses. core clinical features 1. ｏｎ 2. acute myelitis 3. posterior region syndrome, unexplained paroxysmal hiccup, nausea, and vomiting 4. other brainstem syndromes 5. symptomatic episodic sleeping sickness, diencephalic syndrome, brain mri with nmosd characteristic diencephalic lesions 6. cerebral syndrome with nmosd characteristic brain lesions * 4. corticosteroids combined with immunosuppressants (azathioprine or mycophenolate mofetil or rituximab) still relapse after treatment； * 5. at least 2 relapses within the past 12 months or at least 3 relapses within the past 24 months, and at least 1 recurrence within the 12 months prior to screening； * 6. the estimated survival time is more than 12 weeks; * 7. women of childbearing age who have negative urine pregnancy test before medication administration and agree to take effective contraceptive measures during the trial period until the last follow-up exclusion criteria: * 1. epilepsy history or other central nervous system disease; * 2. electrocardiogram shows prolonged qt interval, severe heart diseases such as severe arrhythm ia in the past; * 3. pregnant (or lactating) women; * 4. patients with severe active infections; * 5. active infection of hepatitis b virus or hepatitis c virus; * 6. systemic steroids have used in the 4 weeks before participating in the treatment (except recently or currently using inhaled steroids); * 7. those who have used any gene therapy products before; * 8. the proiferation rate is less than 5 times response to cd3/cd28 co-stimulation signal; * 9. serum creatinine \> 2.5mg/dl or alt / ast \> 3 times uln or bilirubin \> 2.0mg/dl; * 10. those who suffer from other uncontrolled diseases are not suitable to join the study; * 11. hiv infection; * 12. any situation that the researchers believe may increase the risk of patients or interfere with the test results.